Eleanor Cook
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eleanor Cook has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Stella M. Davies
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
4 shared publications- Christopher E. Dandoy
Department of Pediatrics University of Cincinnati College of Medicine Cincinnati Ohio USA
3 shared publications - Pooja Khandelwal
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
3 shared publications - Sonata Jodele
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
3 shared publications Adam Nelson
Kids Cancer Centre Sydney Children's Hospital Sydney New South Wales Australia
2 shared publications- Alan Bidgoli
Division of Blood and Marrow Transplantation, Children's Healthcare of Atlanta, Aflac Blood and Cancer Disorders Center, Emory University, Atlanta, Georgia, USA
2 shared publications
Latest Publications
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2294-2305
Human milk oligosaccharide (2′-FL) modifies the gut microbiome in children after bone marrow transplant
Dysbiosis after allogeneic hematopoietic stem cell transplant (allo-HSCT) predisposes to acute gastrointestinal (GI) graft-versus-host disease (GVHD). Human milk oligosaccharides (HMOs) are prebiotics that establish a favorable intestinal microbiome. We hypothesized that peritransplant HMOs would reduce dysbiosis, and conducted a prospective phase 1/2 study in which 70 patients received oral, daily 2’-fucosyllactose (2’-FL), the most abundant HMO, from start of conditioning through day +30. Primary phase 1 and phase 2 end points were safety and tolerability of 2′-FL and longitudinal preservation of microbiome diversity, respectively. Phase 1 and phase 2 patients with ≥60% adherence were evaluated by correlative analyses. Twenty-nine age-matched patients with available samples in our institutional biorepository served as contemporary controls. 2′-FL was safe and well tolerated on the phase 1 study, which established dosing for the phase 2 study. Shannon diversity was preserved in 2′-FL recipients and declined from baseline to day +30 in controls (P = .04). Generalized linear mixed model analysis revealed higher association of Bifidobacteria and Blautia with 2′-FL (adjusted P< .05). Higher fecal isoleucine (P = .005), tyrosine (P = .05), and taurine (P = .04) were observed in 2′-FL recipients, all associated with protection and regeneration of intestinal epithelium. Lower plasma regulatory islet-derived 3α (P = .053) and suppressor of tumorigenicity 2 levels (P = .038) were observed in 2′-FL recipients compared with controls. Incidence of grade II-IV acute GI GVHD was 0% in 2′-FL recipients compared with 17% in controls (P = .009). Adenovirus reactivation was 0% in 2′-FL recipients compared with 17% in controls (P = .009). 2′-FL is safe and modifies the gut microbiome in children after allo-HSCT. This trial was registered at www.clinicaltrials.gov as #NCT04263597.
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2294-2305
Human milk oligosaccharide (2′-FL) modifies the gut microbiome in children after bone marrow transplant
Dysbiosis after allogeneic hematopoietic stem cell transplant (allo-HSCT) predisposes to acute gastrointestinal (GI) graft-versus-host disease (GVHD). Human milk oligosaccharides (HMOs) are prebiotics that establish a favorable intestinal microbiome. We hypothesized that peritransplant HMOs would reduce dysbiosis, and conducted a prospective phase 1/2 study in which 70 patients received oral, daily 2’-fucosyllactose (2’-FL), the most abundant HMO, from start of conditioning through day +30. Primary phase 1 and phase 2 end points were safety and tolerability of 2′-FL and longitudinal preservation of microbiome diversity, respectively. Phase 1 and phase 2 patients with ≥60% adherence were evaluated by correlative analyses. Twenty-nine age-matched patients with available samples in our institutional biorepository served as contemporary controls. 2′-FL was safe and well tolerated on the phase 1 study, which established dosing for the phase 2 study. Shannon diversity was preserved in 2′-FL recipients and declined from baseline to day +30 in controls (P = .04). Generalized linear mixed model analysis revealed higher association of Bifidobacteria and Blautia with 2′-FL (adjusted P< .05). Higher fecal isoleucine (P = .005), tyrosine (P = .05), and taurine (P = .04) were observed in 2′-FL recipients, all associated with protection and regeneration of intestinal epithelium. Lower plasma regulatory islet-derived 3α (P = .053) and suppressor of tumorigenicity 2 levels (P = .038) were observed in 2′-FL recipients compared with controls. Incidence of grade II-IV acute GI GVHD was 0% in 2′-FL recipients compared with 17% in controls (P = .009). Adenovirus reactivation was 0% in 2′-FL recipients compared with 17% in controls (P = .009). 2′-FL is safe and modifies the gut microbiome in children after allo-HSCT. This trial was registered at www.clinicaltrials.gov as #NCT04263597.
- 24 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (3) , e70001
Central Venous Catheter Removal After Hematopoietic Stem Cell Transplant: A Review and Perspective
Central venous catheters (CVCs) are a cornerstone of hematopoietic stem cell transplantation (HSCT), facilitating the delivery of chemotherapy, parenteral nutrition, medications, and blood products. Despite CVCs’ essential role, prolonged use can lead to complications such as increased risk of infection, thrombosis, mechanical issues, and psychosocial burden. However, the timing of CVC removal remains highly variable across institutions. Additionally, there are no standardized guidelines to balance the benefits of extended access against the risks of prolonged use. This narrative review examines the existing literature on CVC management post‐HSCT, highlighting key factors influencing the removal timing, such as patient characteristics, disease‐specific considerations, and institutional practices. The review emphasizes the urgent need for multi‐institutional research and standardized protocols to improve outcomes, reduce complications, and enhance the quality of care for HSCT patients.
- 24 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (3) , e70001
Central Venous Catheter Removal After Hematopoietic Stem Cell Transplant: A Review and Perspective
Central venous catheters (CVCs) are a cornerstone of hematopoietic stem cell transplantation (HSCT), facilitating the delivery of chemotherapy, parenteral nutrition, medications, and blood products. Despite CVCs’ essential role, prolonged use can lead to complications such as increased risk of infection, thrombosis, mechanical issues, and psychosocial burden. However, the timing of CVC removal remains highly variable across institutions. Additionally, there are no standardized guidelines to balance the benefits of extended access against the risks of prolonged use. This narrative review examines the existing literature on CVC management post‐HSCT, highlighting key factors influencing the removal timing, such as patient characteristics, disease‐specific considerations, and institutional practices. The review emphasizes the urgent need for multi‐institutional research and standardized protocols to improve outcomes, reduce complications, and enhance the quality of care for HSCT patients.
- Open Access
- 13 January 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (3) , 135.e1-135.e10
Oxidative Stress Early After Hematopoietic Stem Cell Transplant
- 13 January 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (3) , 135.e1-135.e10
Open AccessOxidative Stress Early After Hematopoietic Stem Cell Transplant
- Open Access
- 30 December 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (3) , 123-134
Engraft: A Collaborative Learning Health Network for Enhanced Transplant and Cellular Therapy Outcomes
- 30 December 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (3) , 123-134
Open AccessEngraft: A Collaborative Learning Health Network for Enhanced Transplant and Cellular Therapy Outcomes
- Open Access
- 19 April 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (9) , 1634-1643
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant
- 19 April 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (9) , 1634-1643
Open AccessThird-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant
- Open Access
- 22 February 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (5) , 528.e1-528.e12
Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease
- 22 February 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (5) , 528.e1-528.e12
Open AccessRuxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease
- 21 September 2021
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 43 (12) , e141-e145
Utility of Cyclin D1 Immunostaining in Cutaneous Xanthogranuloma
Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase pathway activation has recently been found to be associated with almost all Langerhans cell histiocytosis cases. In BRAF V600E mutation–positive cases, this activation is seen as a downstream activation. In addition, cyclin D1 is a downstream target of the MAPK pathway. Recent studies have argued in favor of using cyclin D1 as a potential neoplastic marker to differentiate Langerhans cell histiocytosis from other reactive Langerhans cell proliferations in the skin and lymph nodes. Therefore, we chose to study the immunohistochemical expression of cyclin D1 in cutaneous xanthogranuloma (XG) cases. Fifteen XG cases were retrieved and stained for cyclin D1, BRAF (v-raf murine sarcoma viral oncogene homolog B1), CD1a, and langerin (CD207). Twelve cases showed strong and diffuse nuclear positivity for cyclin D1, both in the XG cells and in the multinucleated osteoclast-like giant cells. Three cases showed focal weak nuclear staining for cyclin D1. All 15 cases showed negative immunoreactivity for BRAF, CD1a, and CD207. Although limited by small sample size, we conclude that most cases of cutaneous XG should show at least weak nuclear staining with cyclin D1. The histogenesis of XG is still largely unknown, and the finding of cyclin D1 positivity in a majority of cases may indicate a role for the MAPK/extracellular signal-regulated kinase pathway in cutaneous XG.
- 21 September 2021
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 43 (12) , e141-e145
Utility of Cyclin D1 Immunostaining in Cutaneous Xanthogranuloma
Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase pathway activation has recently been found to be associated with almost all Langerhans cell histiocytosis cases. In BRAF V600E mutation–positive cases, this activation is seen as a downstream activation. In addition, cyclin D1 is a downstream target of the MAPK pathway. Recent studies have argued in favor of using cyclin D1 as a potential neoplastic marker to differentiate Langerhans cell histiocytosis from other reactive Langerhans cell proliferations in the skin and lymph nodes. Therefore, we chose to study the immunohistochemical expression of cyclin D1 in cutaneous xanthogranuloma (XG) cases. Fifteen XG cases were retrieved and stained for cyclin D1, BRAF (v-raf murine sarcoma viral oncogene homolog B1), CD1a, and langerin (CD207). Twelve cases showed strong and diffuse nuclear positivity for cyclin D1, both in the XG cells and in the multinucleated osteoclast-like giant cells. Three cases showed focal weak nuclear staining for cyclin D1. All 15 cases showed negative immunoreactivity for BRAF, CD1a, and CD207. Although limited by small sample size, we conclude that most cases of cutaneous XG should show at least weak nuclear staining with cyclin D1. The histogenesis of XG is still largely unknown, and the finding of cyclin D1 positivity in a majority of cases may indicate a role for the MAPK/extracellular signal-regulated kinase pathway in cutaneous XG.